Last edition
News about
Lupin Acquires Two Brands from Sanofi in Europe and Canada
Lupin has announced that its European hub entity, Lupin Atlantis Holdings SA, has completed the acquisition of two well-known brands, Aarane in Germany and Nalcrom in Canada and the Netherlands, along with the associated trademark rights, from Sanofi.
Orchid Pharma Gets DCGI Approval for Enmetazobactam
Orchid Pharma has secured Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam.
Cycle Pharmaceuticals Offers All-Cash Proposal to Acquire Vanda Pharmaceuticals
Cycle Pharmaceuticals Ltd. has confirmed that it proposed to the Board of Directors of Vanda Pharmaceuticals, Inc. to acquire 100 percent of Vanda’s issued and outstanding shares for a cash consideration of USD 8.00 per Vanda share.
Syntegon Acquires Telstar to Expand Pharma Processing and Packaging Space
Syntegon has decided to expand its pharmaceutical processing and packaging business with the acquisition of Azbil Telstar, to date part of the Japanese Azbil Corporation.
CordenPharma Announces Partnership with Certest
CordenPharma has signed a collaboration agreement with Certest, a Spanish company focused on the development of new products with special emphasis in Drug Delivery with LNPs and API synthesis.
Aterian Investment Partners Acquires Contract Pharmaceuticals
Aterian Investment Partners has announced the acquisition of Contract Pharmaceuticals Ltd. Canada, a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.
Dalton Pharma Services Commissions 3P Innovation to Design Robotic Aseptic Powder Filling Line
Dalton Pharma Services has recently commissioned 3P innovation (Warwick, UK) to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line to expedite the delivery of drugs to market in a more compliant, efficient, and economical manner.
Nucleus RadioPharma Receives Series A Extension Funding from AstraZeneca
Nucleus RadioPharma has closed its Series A extension round with new investor AstraZeneca.
Saghmos Gets US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator
Saghmos Therapeutics, Inc. has announced that the US Patent and Trademark Office (USPTO) has granted US Patent No. 11,986,473 titled, 'Prevention and/or Treatment of Contrast-Induced Acute Kidney Injury' for its Phase 3-ready product, ST-62516.
AstraZeneca Completes Acquisition of Fusion
AstraZeneca has completed the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy